Acumen Pharmaceuticals (ABOS) Cash from Investing Activities (2021 - 2026)

Acumen Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 148.13% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at $91.4 million (up 6.42% YoY), while the FY2025 annual figure was $133.9 million, up 178.87% from the prior year.
• Cash from Investing Activities came in at -$13.8 million for Q1 2026 at Acumen Pharmaceuticals, down from $26.2 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $55.9 million in Q3 2022 to a low of -$92.0 million in Q3 2023.
• A 5-year average of $2.1 million and a median of $8.8 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 722.26% in 2023 and surged 499.83% in 2025, its largest moves.
• Acumen Pharmaceuticals' Cash from Investing Activities stood at -$20.4 million in 2022, then sank by 139.02% to -$48.8 million in 2023, then jumped by 160.78% to $29.7 million in 2024, then declined by 11.51% to $26.2 million in 2025, then plunged by 152.6% to -$13.8 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$13.8 million, $26.2 million, and $40.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison